WHC is still in active development. Read this to understand our approach.
depiction of BRUQQQPBMZOVGD-UHFFFAOYSA-N.svg
tripsit

oxycodone

Verificar en tripsit

psychonaut

Oxycodone

Verificar en psychonaut

isomerdesign

Oxycodone

Verificar en isomerdesign

isomerdesign

14-Hydroxy-3-methoxy...

Verificar en isomerdesign

pubchem

Oxycodone

Verificar en pubchem

druglab

Oxycodone

Verificar en druglab

drugmap

Oxycodone

Verificar en drugmap

drugmap

Oxycodone

Verificar en drugmap

wiki

Oxycodone

Verificar en wiki

Data

InChI: InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3

Sinónimos: Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-,Oxycodonum [INN-Latin],Oxicodona,OxyIR,DB00497,Ossicodone,Dihydrone,percocet,Oxicodona [INN-Spanish],OXYCODONE [USAN],Endone,IDS-NO-002,Oxycodone 1.0 mg/ml in Methanol,(-)-14-Hydroxydihydrocodeinone,oxymorphone 3-methyl ether,Eucodalum,14-Hydroxy-3-methoxy-17-(2H3)methyl-4,5α-epoxymorphinan-6-one,Oxicon,PF-00345439,Supendol [Canada],OOX,Dihydroxycodeinone,Roxicodone,Oxycodone Concentrate,Percobarb,NSC19043,EINECS 200-960-2,OXYCODONE [WHO-DD],Codeinone,8-dihydro-14-hydroxy-,(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one,SCHEMBL2737,C08018,(-)-Oxycodone,Endine (Australia),(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one,PTI-821,NSC-19043,DTXSID5023407,Pti 821,oxycodone,Dihydro-14-hydroxycodeinone,CHEBI:7852,OXYCODONE [VANDF],oxycontin,Oxycodone 0.1 mg/ml in Methanol,(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one,Pancodone Retard,Oxicone,4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one,Oxycontin,AC-16043,OXYCODONE CII [USP-RS],(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,Codeinone, dihydrohydroxy-,CD35PMG570,Oxytrex,Oxycodone cii,Oxyneo,UNII-CD35PMG570,Oxycodonum,BDBM50370595,NSC 19043,Apo-oxycodone CR,HSDB 3142,Ossicodone [DCIT],Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-,Oxycodone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,76-42-6,Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-,BRN 0043446,Pancodone retard (United Kingdom),4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-,OXYCODONE [MI],OXYCODONE [INN],Codeinone, 7,8-dihydro-14-hydroxy-,oxy,Oxycodone (USAN/INN),oxynorm,4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one,N02AA05,Dihydrohydroxycodeinone,OXYCODONE [HSDB],Dihydrohydroxycondeinone,Eubine [France],OXYCODONE [ORANGE BOOK],WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1,(5.ALPHA.)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE,Oxycodone,Q407535,Pavinal,Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-,(4R,4aS,7aR,12bS)-4a-Hydroxy-9-methoxy-3-(2H3)methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinolin-7(7aH)-one,(5α)-14-Hydroxy-3-methoxy-17-(2H3)methyl-4,5-epoxymorphinan-6-one,14-Hydroxydihydrocodeinone,14-hydroxy-3-methoxy-17-methyl-5beta-4,5-epoxymorphinan-6-one,Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-,Oxyfast,HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D [EP IMPURITY],Oxycodeinone,Avridi,Xtampza ER,Diphydrone,Oxycodone [USAN:INN:BAN],Tekodin (free base),GTPL7093,Xtampza,Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-,Supendol,4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one,14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one,Codeinone, dihydro-14-hydroxy-,Oxycodon,D05312,ZINC403533,Oxanest,Percodan,PF06,OXYCODONE [MART.],Remoxy,CHEMBL656


Estimated data

Solubilidad: -2.636 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 99.1% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.